Roy Baynes

Company: Eikon Therapeutics

Job title: Executive Vice President and Chief Medical Officer

Seminars:

Initial Promising Data With a Systemically Administered TLR 7 & 8 Coagonist (EIK1001) 9:45 am

Understand the scientific rationale behind EIK1001, a systemically administered agonist of toll-like receptors 7 and 8 Analyze single-agent activity data as well as activity in combination with anti-PD-1 agents across multiple solid tumor types Discuss the program advancing into late stage developmentRead more

day: Conference Day 2